Medico Remedies' credit line more than doubles to ₹42 cr, rating reaffirmed
CRISIL reaffirms BBB-/Stable while enhancing rated facilities by ₹23 cr, a key capacity move for a nano-cap exporter with 37% revenue growth.
— 1 earlier story on Medico Remedies Ltd. →What's new
- CRISIL reaffirmed Medico's long-term rating at BBB-/Stable and short-term at A3.
- Rated facilities more than doubled from ₹19 cr to ₹42 cr across term loan, packing credit, and LC.
- The ₹23 cr increase equals over 12.5% of the company's ₹335 cr market capitalisation.
Why this matters
For a nano-cap pharma exporter, doubling sanctioned credit lines signals bank confidence and provides working capital headroom to support rapid revenue growth. The additional ₹23 cr is meaningful against trailing revenue of ₹206 cr.
What we're watching
- Whether Medico uses the extra borrowing capacity to boost exports (which make up the bulk of sales).
- Impact on the already low debt/equity ratio of 0.22.
- Any follow-on order wins that capitalise on the expanded facilities.
The full read
Medico Remedies just got a significant vote of confidence from its bankers and from CRISIL. The rating agency reaffirmed the BBB-/Stable long-term rating, but the real news is the credit line. Rated facilities more than doubled from ₹19 crore to ₹42 crore, a ₹23 crore jump representing over 12.5% of Medico's ₹335 crore market cap. For a nano-cap pharma exporter with trailing revenue growth of 37% and a debt/equity of just 0.22, this is not a routine reaffirmation. It is a capacity upgrade. The facilities from Kotak Mahindra Bank include term loan, packing credit, and LC, directly supporting export order execution. With FY26 revenue of ₹206 cr and exports dominating, the extra headroom could help Medico seize larger or faster-turn orders. The open question: will it use the line to push growth further or simply as a buffer? The stable rating suggests CRISIL sees the continued strength in the business.
Questions answered
- Why did CRISIL reaffirm Medico's rating at BBB-/Stable?
- The rating reflects Medico's strong revenue growth and export-oriented business, with a stable outlook indicating expectation of sustained performance.
- What does the enhancement from ₹19 cr to ₹42 cr mean for the company?
- The ₹23 cr increase more than doubles Medico's access to bank credit, now representing over 12.5% of its market cap. This supports working capital for scaling operations.
- How significant is a ₹23 cr credit enhancement for a company with ₹206 cr revenue?
- It is notable: the additional credit line equals about 11% of FY26 revenue, giving Medico substantial headroom to fund growth without diluting equity.
- Does the reaffirmation alter Medico's capital structure?
- Not directly, but the enhanced facilities allow Medico to potentially increase borrowings from a low base. Its current debt/equity is just 0.22.
Medico Remedies Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on MEDICO →- 29 Jun 2026 · 6:14 PM IST Medico Remedies' credit line more than doubles to ₹42 cr, rating reaffirmed
- 46d ago Medico Remedies closes FY26 with 37% revenue growth, no surprises